“These guidances will help companies establish clear, well-understood compliance programs so that their relationships with these third-parties will be focused on what is best for patients. MEDEC’s approval of these guidances will help ensure the integrity of medical decision-making and promote further public confidence in our industry.”
The Advanced Medical Technology Association (AdvaMed) today issued a statement by Stephen J. Ubl, president and CEO, commending a call by Members of Congress for the Office of the Inspector General (OIG) to study the impact of competitive bidding on patients.
“AdvaMed applauds the subcommittee for holding this important hearing on barriers to evidence development and improving communication and collaboration among patients, providers, researchers, and medical technology companies to ensure continued development of the latest treatments and cures.
WIIT’s newly appointed president is Nancy S. Travis, vice president, international compliance and governance at AdvaMed (the Advanced Medical Technology Association).
“The new Milken Institute report released today is an important assessment on how improved patient access to innovative medical technology can provide tremendous value to the U.S. economy, both now and in the future.
“AdvaMed commends the House for taking action on legislation to address another component of the tax code that is important to innovative and emerging growth medical technology companies.
Medical technology prices continue their trend of consistently low growth, increasing at approximately one-third the rate of prices in the overall economy and one-fifth the rate of prices for other medical goods and services over a 23-year period, according to an updated study released today by the Advanced Medical Technology Association (AdvaMed).
“As AdvaMed continues to expand its focus on emerging markets in the Asia-Pacific region and around the world, we applaud Ms. Weisel’s leadership in developing and implementing U.S. trade policy that helps ensure patient access to innovative, life-saving and life-enhancing treatments and cures.
“AdvaMed applauds the subcommittee for holding this important hearing on the adequacy of current economic and regulatory incentives designed to foster R&D investment in innovative medical devices, diagnostics and pharmaceuticals.